1.Rini B et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma, N Engl J Med 2019 Mar 21;380 (12) : 1116-1127

2.Fizazi K et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial, Lancet 2019 May; 20 (5) : 686 - 700

3. Fizazi K, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. Randomized controlled trial, N Engl J Med 2019 March 28; 380 : 1235 - 1246

4. Davis I, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer, N Engl J Med 2019 July 11; 381: 121 - 131

5.  Chi K, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer, N Engl J Med 2019 July 4; 381: 13 - 24

6. Y Fradet et al. Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up, Annals of Oncology Vol. 30 , Issue 6, June 2019; 970 – 976

7. Urinary biomarkers in bladder cancer. Where do we stand. Current Opinion in Urology 2019, June

8. Govers TM, Caba L,Resnick MJ,Cost-efectiviness of urinary biomarker Panel in Prostate Cancer Risk Assesment. J.Urol.2018 Dec;200(6):1221-1226

9. Perlis N, Al-Kasab T, Ahmad A, et al. Defining a cohort that may not require repeat prostate biopsy based on pca3 score and magnetic ressonance Imaging: the dual negative effect. J.Urology.2018 May; 199(5): 1182-1187

10.Head-to-Head Comparison of Transrectal US-Guided Prostate Biopsy vs. mpMRI with Subsequent MRI-Guided Biopsy in Biopsy-Naïve Men with Elevated PSA (Eur Urol 2019)

11.Multicentre Study of 5-year Outcomes Following Focal Therapy (Eur Urol 2018)

12.CARMENA Sunitinib Alone or After Nephrectomy in Metastatic Renal-Cell Carcinoma (NEJM 2018)

13.Comparison of Costs of Radical Cystectomy vs. Trimodal Therapy for Patients With Localized Muscle Invasive Bladder Cancer (JAMA 2019)

14.Prevalence of HPV DNA and p16INK4a in Penile Cancer (Lancet Oncol 2018)

15. A 16-yr Follow-up of the ERSPC (Eur Urol 2019)